Diagnostics CEOs In Triplicate Weigh In On Upcoming Hurdles
Tune in to this one-off podcast feature discussing the state-of-play in the diagnostics sector, with guests from ImmunExpress, Lucid Diagnostics and ChromaCode.
You may also be interested in...
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.
Freenome, the Roche-backed early cancer detection liquid biopsy developer has raised yet more money, making it one of the best-funded companies in its sub-sector. With trial results due relatively soon, investors are likely hoping this will be the last funding round required before full commercialization.
Osso VR’s platform for the simulation of orthopedic surgical procedures could solve several issues facing the field, according to CEO Justin Barad.